Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Down 87.2% in July

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw a large decrease in short interest in the month of July. As of July 15th, there was short interest totaling 20,246 shares, a decrease of 87.2% from the June 30th total of 158,023 shares. Based on an average daily volume of 9,139 shares, the days-to-cover ratio is presently 2.2 days. Currently, 0.0% of the company’s shares are sold short.

Institutional Investors Weigh In On Ascentage Pharma Group International

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. UBS Group AG raised its holdings in shares of Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares during the period. Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International during the 2nd quarter worth about $391,000. Finally, Citadel Advisors LLC acquired a new stake in Ascentage Pharma Group International during the 3rd quarter worth approximately $383,000.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. B. Riley Financial initiated coverage on Ascentage Pharma Group International in a research report on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price objective for the company. BTIG Research reiterated a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a research report on Monday, June 15th. China Intl Cap raised Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, April 6th. Deutsche Bank Aktiengesellschaft began coverage on Ascentage Pharma Group International in a research note on Friday, April 24th. They issued a “buy” rating and a $40.00 price target on the stock. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. Two research analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $46.43.

Ascentage Pharma Group International Stock Down 5.4%

Shares of AAPG opened at $18.29 on Friday. The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57. The stock’s fifty day simple moving average is $18.56 and its 200 day simple moving average is $22.42. Ascentage Pharma Group International has a twelve month low of $16.36 and a twelve month high of $48.45.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.